These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25827645)

  • 1. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.
    Gougol A; Zareh-Mohammadi N; Raheb S; Farokhnia M; Salimi S; Iranpour N; Yekehtaz H; Akhondzadeh S
    J Psychopharmacol; 2015 May; 29(5):575-81. PubMed ID: 25827645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Salagre E; Fernandes BS; Dodd S; Brownstein DJ; Berk M
    J Affect Disord; 2016 Aug; 200():235-42. PubMed ID: 27148902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
    Jazayeri S; Tehrani-Doost M; Keshavarz SA; Hosseini M; Djazayery A; Amini H; Jalali M; Peet M
    Aust N Z J Psychiatry; 2008 Mar; 42(3):192-8. PubMed ID: 18247193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial.
    Salardini E; Zeinoddini A; Mohammadinejad P; Khodaie-Ardakani MR; Zahraei N; Zeinoddini A; Akhondzadeh S
    J Psychiatr Res; 2016 Apr; 75():24-30. PubMed ID: 26800392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
    J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder.
    Haghighi M; Khodakarami S; Jahangard L; Ahmadpanah M; Bajoghli H; Holsboer-Trachsler E; Brand S
    J Psychiatr Res; 2014 Nov; 58():109-14. PubMed ID: 25130678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder.
    Khoraminya N; Tehrani-Doost M; Jazayeri S; Hosseini A; Djazayery A
    Aust N Z J Psychiatry; 2013 Mar; 47(3):271-5. PubMed ID: 23093054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial.
    Abbasi SH; Mohammadinejad P; Shahmansouri N; Salehiomran A; Beglar AA; Zeinoddini A; Forghani S; Akhondzadeh S
    J Affect Disord; 2015 Sep; 183():149-55. PubMed ID: 26005776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response.
    Sanacora G; Berman RM; Cappiello A; Oren DA; Kugaya A; Liu N; Gueorguieva R; Fasula D; Charney DS
    Neuropsychopharmacology; 2004 Jun; 29(6):1166-71. PubMed ID: 15010697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
    Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
    J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
    Magid M; Reichenberg JS; Poth PE; Robertson HT; LaViolette AK; Kruger TH; Wollmer MA
    J Clin Psychiatry; 2014 Aug; 75(8):837-44. PubMed ID: 24910934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Roohi-Azizi M; Arabzadeh S; Amidfar M; Salimi S; Zarindast MR; Talaei A; Akhondzadeh S
    Clin Neuropharmacol; 2017; 40(1):1-5. PubMed ID: 28085707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial.
    Strik JJ; Honig A; Lousberg R; Lousberg AH; Cheriex EC; Tuynman-Qua HG; Kuijpers PM; Wellens HJ; Van Praag HM
    Psychosom Med; 2000; 62(6):783-9. PubMed ID: 11138997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.